Cervical cancer (CC) is a major health threat to women, with immunotherapies targeting the programmed death receptor 1/programmed death ligand 1(PD‐1/PD‐L1) axis showing promise but encountering resistance in a significant patient population. The gene discussed is CD274; the disease is cervical cancer.